Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

Multiple Cancer Types

This phase Ib trial studies the side effects and best dose of venetoclax and selinexor and how well they work in treating patients with high risk hematologic malignancies such as diffuse large B-cell lymphoma, multiple myeloma, or acute myeloid leukemia that have come back (recurrent) or do not respond to treatment (refractory). Venetoclax functions by inhibiting or slowing down a protein in the body called bcl-2, which is involved in slowing down the normal process by which old cells in the body are cleared (called apoptosis). Selinexor functions by trapping tumor suppressing proteins within the cell and causing the cancer cells to die or stop growing. This study examines the effects, if any, of selinexor and venetoclax on high risk hematologic malignancies and on the body, including any side-effects.
Hematologic, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, Phase I
I
Mohan, Sanjay
NCT03955783
VICCHEM1755

A Study to Evaluate Safety and Efficacy of Selinexor in Combination With Ruxolitinib in Participants With Myelofibrosis

Multiple Cancer Types

This is a global, Phase 1 / 2, multicenter, open-label study to evaluate the safety and efficacy of selinexor plus ruxolitinib in treatment nave myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1a / 1b and Phase 2. The Phase 1a of the study will be dose escalation (non-randomized dose finding study) to determine the maximum tolerated dose [MTD], recommended Phase 2 dose (RP2D), and evaluate safety and preliminary efficacy and will follow a standard 3+3 design. The Phase 1b of the study will be dose expansion (non-randomized efficacy exploration) at the determined RP2D to further assess the safety and preliminary efficacy at this dose level. The Phase 2 (randomized efficacy exploration) of the study will include MF participants who are treatment nave randomized 1:1 to receive the combination therapy of selinexor and ruxolitinib versus (vs) ruxolitinib monotherapy.
Hematologic, Phase I
I/II
Mohan, Sanjay
NCT04562389
VICCHEMP2130

Selinexor with or without Docetaxel for the Treatment of Stage IV KRAS Mutant Non-small Cell Lung Cancer

Multiple Cancer Types

This phase I / II trial studies the safety and best dose of selinexor with or without docetaxel in treating patients with stage IV KRAS-mutation non-small cell lung cancer that has spread to other places in the body. Selinexor may stop the growth of tumor cells by blocking CRM1, a protein needed for tumor cell survival. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Giving selinexor with or without docetaxel may kill more tumor cells in patients with stage IV KRAS mutant non-small cell lung cancer.
Lung, Non Small Cell
I/II
York, Sally
NCT03095612
VICCTHO1791

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: